Latest Mankind Pharma News
All-In-One Mankind Pharma Stock News Hub: Explore the latest Mankind Pharma stock and industry news. Quickly find information on Mankind Pharma stock buybacks,Mankind Pharma results, Mankind Pharma company analysis, Mankind Pharma live prices, Mankind Pharma dividends, Mankind Pharma bonus share, board meetings, lifetime highs, Mankind Pharma targets, lows, and growth stories with AI.
Business Standard
Mankind Pharma board to consider fund raising on Sep 20
The pharma major informed that a meeting of its board is scheduled to be held on Friday, 20 September 2024 to mull the fund raising proposal for an amount as may be decided.
•
Wed, Sep 18, 2024
The Economic Times
Stocks in news: VST Industries, Torrent Power, REC, Tata Power, Mankind Pharma
Torrent Power has received Letter of Intent (LOI) from Maharashtra State Electricity Distribution Co. Limited (MSEDCL) for procurement of 1,500 MW/ 12,000 MWh energy storage capacity for pumped hydro storage project.
•
Wed, Sep 18, 2024
The Economic Times
Mankind Pharma board to meet this week to consider fund raising
Mankind Pharma is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and consumer healthcare products.
•
Wed, Sep 18, 2024
CNBC TV18
Mankind Pharma to consider fund raising plans on September 20
Shares of Mankind Pharma ended 0.2% lower at ₹2,452.00 per share.
•
Tue, Sep 17, 2024
The Economic Times
Nifty closed the week with 2% gains, despite significant block deals totaling Rs 10,934 crore across large, mid, and smallcap companies. Tata Group's Trent led largecap block deals with Rs 715 crore, followed by Mankind Pharma, Tube Investments of India, Bosch, and others.
•
Sat, Sep 14, 2024
CNBC TV18
Mankind Pharma transfers OTC business to unit via slump sale agreement
Under the deal, Mankind Pharma will divest its OTC business, which includes a range of non-prescription products, to Mankind Consumer Products.
•
Tue, Sep 3, 2024
CNBC TV18
GIC Re, GSK Pharma, Godfrey Phillips, IEX and more: Top stocks to watch out for on September 4
stocks to watch, GIC Re, GSK Pharma, Godfrey Phillips, IEX, Zydus Lifesciences, KIMS, AU Small Finance Bank, PDS, ZEEL, Hitachi Energy, NHPC, Mankind Pharma and more, these are the stocks to watch for today.
•
Tue, Sep 3, 2024
The Economic Times
Mankind: How Meerut brothers built India's 4th largest pharma firm
Mankind Pharma has announced a significant move by acquiring Bharat Serums and Vaccines Ltd for Rs 13,630 crore. The acquisition, partly funded by debt, aims to strengthen Mankind’s portfolio. The Juneja brothers are confident in their strategy despite market concerns about integration and cost.
•
Tue, Sep 3, 2024
Business Standard
Mankind up 3% after reports say co looking to raise Rs 9k cr for BSV deal
Mankind Pharma is likely to raise Rs 9,000 crore through NCDs to acquire Bharat Serums and Vaccines
•
Tue, Sep 3, 2024
Business Standard
Mankind Pharma plans Rs 9,000 crore raise for Bharat Serums acquisition
The move will position Mankind as a leader in the gynaecology-fertility segment, with an anticipated market share of around 20%, surpassing Emcure
•
Tue, Sep 3, 2024
The Economic Times
Mankind Pharma eyes ₹9,000 cr via debt to stitch BSV deal
The average blended cost of the debt is likely to be around 8.50% with the firm seeking to borrow money over one- to-five years, said three people familiar with the plans. "Bankers have already approached large mutual funds to place the debt, which will range from one year and may go up to five years looking at the demand," said one of the persons.
•
Mon, Sep 2, 2024
Mint
Pharma stocks see 3rd straight month of gains in August, Mankind Pharma and 6 others rise up to 23%
Pharma stocks continued their bullish trend in August, with the Nifty Pharma index rising by 6.61%, driven by strong performances from Mankind Pharma and others. The index has gained 36% this year, benefiting from increased US sales, new product launches, and strong quarterly earnings.
•
Mon, Sep 2, 2024
The Economic Times
Mankind can clear debt taken for BSV buy in 3 years: MD Rajeev Juneja
Mankind Pharma aims to clear its ₹13,630-crore debt from acquiring Bharat Serums and Vaccines within three years, according to MD Rajeev Juneja. He was optimistic about using Mankind's reach and marketing skills to expand BSV's range. The successful integration of Panacea in 2022, despite initial doubts, was cited as a positive precedent.
•
Wed, Aug 14, 2024
The Economic Times
Delhi High Court urges quick decision on Mankind Pharma's plea against Mercykind Pharmaceuticals
The Delhi High Court instructed its single judge bench to swiftly reconsider Mankind Pharma's request to block Chandra Mani Tiwari from using the name Mercykind Pharmaceuticals. The court took note of alleged 'dishonest adoption' and changes in Tiwari's branding. Mankind Pharma had sought this due to trademark concerns but was previously denied an injunction in 2018.
•
Tue, Aug 13, 2024
Business Standard
Oyo founder Ritesh Agarwal invests Rs 830 cr in firm's latest funding round
Besides Agarwal, key contributors in the funding round include InCred Wealth, J&A Partners, the family office of Mankind Pharma promoters and ASK Financial Holdings
•
Mon, Aug 12, 2024
Hindustan Times
OYO raises ₹1,457 crore in latest funding round for growth and global expansion
OYO raises ₹1,457 crore including contributions from InCred Wealth, J&A Partners, the family office of Mankind Pharma promoters and ASK Financial Holdings.
•
Sun, Aug 11, 2024
Business Line
What should you do with the Mankind Pharma stock post the Bharat Serums and Vaccines acquisition?
Synergies arising from the Bharat Serums acquisition could play out over the long term, benefitting Mankind shareholders
•
Sat, Aug 10, 2024
The Economic Times
Mankind Pharma in licensing pact with Takeda to market acidity drug Vonoprazan in India
Mankind Pharma partners with Takeda to introduce Vonoprazan for GERD, oesophagitis, ulcers, and Helicobacter pylori in India. EVP Ramesh stresses business growth. Collaborations with AstraZeneca (Symbicort) and Novartis (Neptaz) enhance their strategy. In-licensing, including royalties on sales, expands domestic formulations using local sales networks, improving access to innovative therapies.
•
Tue, Jul 16, 2024
Business Standard
CPPIB sells stakes in Delhivery, Nykaa; Capital Group in Mankind
Canada Pension Plan Investment Board pared its holdings on Wednesday, in FSN E-Commerce Ventures (Nykaa) and Delhivery
•
Thu, Jul 11, 2024
Business Line
Mankind Pharma front-runner to buy Bharat Serums, binding bids yet to be submitted
From a 52-week low of ₹1,661.05 in July 2023, the company’s shares rose to a high of ₹2,490 in April 2024, though it has come off those highs now
•
Wed, Jul 3, 2024